EYPT Overview

Company Profile

Related stocks

CBIO • United States

Crescent Biopharma, Inc.

14.91 USD

553.86M USD 1Y +17.1%

MNPR • United States

Monopar Therapeutics Inc.

78.96 USD

529.99M USD 1Y -14.8%

DSGN • United States

Design Therapeutics, Inc.

11.65 USD

729.08M USD 1Y +65.6%

SGP • United States

SpyGlass Pharma, Inc.

24.92 USD

833.52M USD

PROK • United States

ProKidney Corp.

1.74 USD

694.58M USD 1Y -49.1%

CRMD • United States

CorMedix Inc.

7.38 USD

575.23M USD 1Y -35%

JBIO • United States

Jade Biosciences, Inc.

14.39 USD

915.17M USD 1Y +55.8%

ODTX • United States

Odyssey Therapeutics, Inc.

19 USD

913.11M USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

4 Metrics

Country

Region

Sector

Industry

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

123.4% p.a.

Max Drawdown (5Y)

-89.4%

Sharpe Ratio (5Y)

-0.18

Beta Factor

1.68

Size Class

Micro Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

High market risk: Beta of 1.68 indicates above-average volatility compared to the broader market.

Elevated Short-Term Volatility: 3Y volatility (136.9%) is noticeably higher than the 5Y average (123.4%).

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (123.4% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -94.0% in the extended horizon.